- AXGN Dashboard
- Financials
- Filings
-
Holdings
- Transcripts
- ETFs
- Insider
- Institutional
- Shorts
-
S-8 Filing
AxoGen (AXGN) S-8Registration of securities for employees
Filed: 9 Aug 24, 4:36pm
Exhibit 107
Calculation of Filing Fee Tables
Form S-8
(Form Type)
Axogen, Inc.
(Exact Name of Registrant as Specified in its Charter)
Table 1: Newly Registered Securities
Security Type | Security Title | Fee Calculation Rule | Amount Registered(1) | Proposed Offering | Maximum Price | Fee Rate | Amount of Registration | |||||||
Equity | Common Stock, $0.01 par value per share | Other(3) | 2,500,000(2) | $7.60 | $19,000,000 | .00014760 | $2,804.40 | |||||||
Equity | Common Stock, $0.01 par value per share | Other(3) | 1,050,000(4) | $7.60 | $7,980,000 | .00014760 | $1,177.85 | |||||||
Total Offering Amounts | $26,980,000 | $3,982.25 | ||||||||||||
Total Fee Offsets | — | |||||||||||||
Net Fee Due | $3,982.25 |
(1) | Pursuant to Rule 416 under the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement shall also cover any additional shares of common stock, $0.01 par value (the “Common Stock”) of Axogen, Inc. (the “Registrant”), which become issuable under the Axogen, Inc. Third Amended and Restated 2019 Long-Term Incentive Plan (the “Second Amended 2019 Plan”) by reason of any stock dividend, stock split, recapitalization or any other similar transaction effected without receipt of consideration which results in an increase in the number of the Registrant’s outstanding shares of Common Stock. |
(2) | Represents an additional 2,500,000 shares of Common Stock of the Registrant issuable under the Third Amended 2019 Plan. |
(3) | Estimated solely for the purpose of calculating the registration fee pursuant to Rules 457(c) and 457(h) under the Securities Act, based on the average of the high and low sales prices of the Common Stock as reported on The Nasdaq Capital Market on August 5, 2024, which was $7.60 per share. |
(4) | Represents 1,050,000 shares of Common Stock of the Registrant issuable upon the settlement of performance stock units granted to Michael Dale on August 9, 2024, outside of the Axogen, Inc. Amended and Restated 2017 Employee Stock Purchase Plan and the Axogen, Inc. Inducement Equity Incentive Plan as an inducement material to entry into employment with the Registrant, in accordance with Nasdaq Listing Rule 5635(c)(4). |